Parexel's Reorganized Research Segment Includes Small-Company Specialty
Executive Summary
Parexel will create a unit dedicated to small biotech and pharmaceutical businesses as part of a reorganization of the company's contract research segment.
You may also be interested in...
Barnett International
Parexel subsidiary names Marcus Wadsworth VP-chief consultant, a new position. Wadsworth will be responsible for strategic consulting within the pharmaceutical/biotech/medical devices arena, expanding the company's strategy consulting business segment to complement its implementation consulting offerings (1"The Pink Sheet" Nov. 1, p. 9). Wadsworth previously served as North American life sciences practice leader at Gemini Consulting LLC
Barnett International
Parexel subsidiary names Marcus Wadsworth VP-chief consultant, a new position. Wadsworth will be responsible for strategic consulting within the pharmaceutical/biotech/medical devices arena, expanding the company's strategy consulting business segment to complement its implementation consulting offerings (1"The Pink Sheet" Nov. 1, p. 9). Wadsworth previously served as North American life sciences practice leader at Gemini Consulting LLC
Quintiles Increases Contract Win Rate But Suffers From Halt Of Antiplatelets
Quintiles has won about 550 contract bid proposals for drug development work in the U.S. during the first seven months of 1999, according to figures on its success rate provided to analysts during a Sept. 17 conference call.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: